Business Context and Reporting Period
This Form 8-K was filed by GlycoMimetics, Inc. (trading symbol: GLYC) on December 19, 2024. The report addresses a regulatory notice regarding the continued listing of the company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on listing status and stock price compliance rather than financial performance metrics.
Material Changes
- Listing Transfer: Effective December 20, 2024, the company's common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market.
- Compliance Extension: Nasdaq granted the company an additional 180 calendar days (until June 16, 2025) to regain compliance with the minimum closing bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
Management intends to actively monitor the bid price of its common stock through June 16, 2025. To regain compliance, the company may consider available options, including effecting a reverse stock split if necessary. There is no assurance that the company will regain compliance or avoid delisting. If compliance is not demonstrated by the deadline, Nasdaq will notify the company of delisting, at which point the company may appeal the determination to a Nasdaq Hearings Panel.
Investor Verification Checklist
- Verify the current closing bid price of GLYC stock to assess proximity to the $1.00 compliance threshold.
- Monitor for any future announcements regarding a reverse stock split or other capital structure changes.
- Track the June 16, 2025 deadline for final compliance determination.
- Review the implications of trading on the Nasdaq Capital Market versus the Nasdaq Global Market for liquidity and visibility.